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Abstract
There is intense interest in developing therapeutic strategies for RAS proteins, the most frequently 
mutated oncogene family in cancer. Development of effective anti-RAS therapies will be aided by 
the greater appreciation of RAS isoform-specific differences in signaling events that support 
neoplastic cell growth. Recognition that there are RAS mutation-specific differences has led to 
expectations that defining RAS mutation-selective vulnerabilities will lead to new therapies. 
However, critical issues remain that require resolution to facilitate the success of these efforts. In 
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particular, the use of well-validated anti-RAS antibodies is essential for accurate interpretation of 
experimental data. We evaluated 22 commercially available RAS antibodies using a set of unique 
and innovative reagents and cell lines. We validated antibodies for each of the four RAS isoforms, 
and for G12D- or G12V-mutant RAS proteins, for Western blot but not for immunofluorescence 
(IF) or immunohistochemical (IHC) analyses. Our results may help ensure accurate interpretation 
of future RAS studies.
INTRODUCTION
The three RAS genes (HRAS, KRAS and NRAS) comprise the most frequently mutated 
oncogene family in cancer, with an overall 27% missense mutation frequency in all human 
cancers (COSMIC v80) (1–3). RAS mutation frequency is highly tissue context-dependent, 
with highest frequencies observed in lung, colorectal and pancreatic ductal adenocarcinoma 
(PDAC).
RAS genes encode four structurally and biochemically highly related 188–189 amino acid 
proteins (4). KRAS encodes two proteins, KRAS4A and KRAS4B, due to alternative fourth 
exon utilization (5–8). RAS proteins exhibit 82–90% overall amino acid sequence identity 
(9) and 93–99% sequence identity within the amino-terminal G domain (residues 1–164) 
(10). In sequences involved in interaction with the guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs) that regulate GDP-GTP cycling, and in 
activation of downstream effectors (e.g., RAF), this region is invariant. In contrast, RAS 
proteins show only 8% sequence identity in the carboxyl-terminal hypervariable region 
(residues 165–184/185). Caax tetrapeptide motif-signaled posttranslational lipid 
modifications, an isoform-dependent process of prenylation and methylation, combined with 
the divergent hypervariable region, determine RAS intracellular trafficking and membrane 
interactions and contribute to RAS isoform-distinct biological functions. One issue now 
recognized, yet still poorly understood, is that the four RAS protein isoforms, despite their 
near-identical structure and biochemistry, serve distinct roles as cancer drivers (3, 9).
The three RAS genes are not mutated at comparable frequencies in human cancers. KRAS is 
by far the most commonly mutated (84%), followed by NRAS (12%), and HRAS (4%) (1). 
Additionally, there are tissue-specific preferences for the specific RAS gene mutated. For 
example, KRAS is exclusively the RAS isoform mutated in PDAC, whereas NRAS is the 
predominant (94%) isoform mutated in cutaneous melanoma, and HRAS mutations are 
favored (86%) in head and neck squamous cell carcinoma. Limited evidence that these 
frequencies reflect tissue-specific functions comes from mouse models of cancer. For 
example, KrasG12D but not NrasG12D promoted colon cancer development in Apc-deficient 
mice (11). Expression of activated KrasG12V and HrasG12V under control of the same 
regulatory sequences resulted in different types of tumors (12).
Cancer-associated RAS genes contain missense mutations that result in single amino acid 
substitutions; 99% are found at one of three mutational hotspots, glycine-12 (G12), 
glycine-13 (G13) or glutamine-61 (Q61) (1, 9, 13). G12 mutations comprise 83% of all 
KRAS mutations, followed by G13 mutations (14%), whereas Q61 mutations are rare (2%). 
In striking contrast, Q61 is the predominant mutational hotspot in NRAS (62%), followed by 
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G12 (23%), and then G13 (12%). These frequencies suggest that G12 and Q61 mutations 
may have distinct consequences for different RAS isoforms. That NrasQ61R but not 
NrasG12D potenti caused melanoma development in Ink4a-deficient mice supports this 
possibility (14). Finally, although there are six possible single base missense mutations at 
each codon, the frequencies with which they occur are not uniform. It has also become 
evident that RAS mutant proteins exhibit distinct biochemical deficiencies (15, 16). An 
emerging premise in the field is that the different RAS mutations are not created equal and 
that the identification of mutation-selective differences will identify unique vulnerabilities 
that can then be exploited to develop mutation-selective therapies (17). The development of 
RAS inhibitors that are selective for one RAS mutation, G12C, represents this shift in the 
field (18, 19).
Antibodies are essential reagents in biomedical research, but poor quality antibodies are a 
major cause of the “reproducibility crisis” in understanding protein function and in the 
pathway to new drugs (20–22). This crisis, and the related need for better characterized and 
validated antibodies, is exemplified by a report that 47 of 53 landmark cancer research 
papers from the early 2000s could not be replicated (23). It has been estimated that fewer 
than half of the 6,000 commercially available antibodies recognize their advertised targets 
(21) and that $800 million annually is spent on poor quality antibodies ($350 million in the 
USA alone) (22). There are also numerous examples of antibody problems slowing medical 
progress. In 2009, a research group secured federal funding to stratify melanoma patient 
treatment regimens based on quantitative immunofluorescence staining of biopsy samples 
(24). However, they were forced to abandon this project because subsequent lots of 
antibodies from the same source no longer generated the same results on the same tumor 
samples (20). Further, another research group spent two years, thousands of patient samples, 
and $500,000 before realizing that the antibody they had been using for early detection of 
pancreatic cancer was recognizing the wrong protein (20), an astounding disappointment for 
pancreatic cancer patients, whose 5-year survival rate is an abysmal 8% (25). Nevertheless, 
despite extensive efforts of organizations such as the International Working Group on 
Antibody Validation, two International Antibody Validation Meetings, and crowd-funded 
scientific websites such as www.antybuddy.com (26, 27), the quality of commercially 
available antibodies and their degree of validation remain decidedly mixed.
With renewed interest in RAS and with new investigators entering the field (28, 29), we 
believe that now is an ideal time to revisit validation of RAS antibodies. To ensure the 
accuracy of our own studies and as a service to the field, we analyzed 22 commercially 
available RAS antibodies for their specificity and sensitivity in recognizing individual RAS 
isoforms. Our analyses demonstrate that the properties of many of these antibodies have not 
been accurately established. Our results support the likelihood that the conclusions from 
some RAS research have been compromised by misinterpretation of data due to faulty 
information regarding RAS antibody properties. Moving forward, we hope that our 
validation of antibodies for specific applications will facilitate greater reliability in future 
RAS studies.
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RESULTS
Evaluation of RAS isoform selectivity against recombinant RAS proteins
We purified unprocessed wild-type full length human KRAS4B, HRAS, and NRAS proteins 
from E. coli. Additionally, both unprocessed and processed (farnesylated, proteolyzed and 
methylated) KRAS4B and KRAS4A were purified from insect cells as we described (30). 
Three concentrations of each purified RAS protein were resolved by SDS-PAGE to verify 
size and purity (Fig. 1A). KRAS bands appear slightly more intense across the blot, likely 
because of their lysine-rich C-terminal HVR sequences detected by the negatively charged 
Coomassie staining method. Notably, unprocessed KRAS4A protein from insect cells 
purified as two species, a minority of the full-length protein, and a major species that, based 
on mass spectrometry results, lacks the last five amino acids. Otherwise, RAS proteins were 
highly pure (>95%) and migrated at the expected molecular weight for full length proteins.
We analyzed a panel of 22 commercially available RAS antibodies (Table 1) that includes 
those most widely cited in the literature. Also included in this panel were four monoclonal 
antibodies generated against human KRAS4B protein by the NCI RAS Initiative at the 
Frederick National Laboratory for Cancer Research (FNLCR) that have not yet been used in 
any published studies. We interrogated each antibody for RAS isoform selectivity and 
sensitivity, and asked whether Caax-signaled processing influenced recognition of KRAS 
proteins (Figs. 1, B–D). Most antibodies recognized their intended target, but there were 
some exceptions.
No antibody described as having pan-RAS selectivity uniformly recognized all RAS 
isoforms. Ras10 (05–516) showed fairly equivalent recognition of all RAS isoforms and was 
not influenced by KRAS4B processing. However, another pan-RAS antibody (05–1072) was 
more selective for HRAS and for unprocessed KRAS4A than for other RAS proteins. Three 
of the four FNLCR-generated antibodies recognized all the RAS proteins, even though the 
immunogen used was recombinant full length KRAS4B (Fig. 1B). Notably, the FNLCR 
CPTC-KRAS4B-2 antibody showed pan-RAS sensitivity that was superior to any of the 
commercially available pan-RAS antibodies we tested.
Two HRAS-specific (SC-520 and 18295–1-AP) and two NRAS-specific (SC-31 and 
SC-519) antibodies showed strong selectivity for their intended targets, with no recognition 
of the other RAS isoforms (Fig. 1C). However, one antibody intended to be NRAS-specific 
(10724–1-AP) only weakly recognized NRAS at the highest protein abundance and instead 
more effectively recognized other RAS isoforms.
We evaluated three commercially available KRAS4A/4B antibodies (Fig. 1D). Two 
antibodies (SC-30 and OP24) recognized unprocessed and processed versions of both KRAS 
isoforms, whereas another (WH0003845M1) showed strong selectivity for KRAS4B with a 
higher affinity for unprocessed protein, and did not recognize KRAS4A. We evaluated three 
KRAS4A-specific antibodies [6156–1-AP, SC-522 (C-17) and ABC1422], none of which 
recognized KRAS4B (Fig. 1D). However, all three showed significantly stronger recognition 
of unprocessed than processed KRAS4A. This is not entirely surprising, given that the Caax-
signaled posttranslational modifications are immediately adjacent to the major sequence 
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differences between KRAS4A and KRAS4B and may therefore disrupt epitope recognition 
of antibodies generated against purified bacterial proteins that lack such modifications. The 
two KRAS4B-selective antibodies recognized purified KRAS4B but did not recognize 
KRAS4A. One of these (16155–1-AP) recognized both unprocessed and processed 
KRAS4B proteins with comparable signal strength (Fig. 1D). In contrast, the other (SC-521) 
recognized only unprocessed KRAS4B protein, even though the antibody was generated 
against the human KRAS4B carboxyl-terminus. Processed KRAS4B may not be recognized 
because the antibody epitope overlaps with the cleaved Caax fragment that is removed 
during processing.
Evaluation of RAS isoform selectivity in lysates of engineered mouse cells
We next investigated how well the antibodies performed when probing cell lysates from cells 
deficient in any Ras genes (henceforth called Rasless MEFs) and rescued by BRAFV600E or 
exogenous expression of a single RAS isoform. This approach took advantage of an 
innovative cell model developed by Barbacid and colleagues (31). Rasless MEFs are derived 
from Hras−/−/Nras−/− mice harboring a conditional Kras allele that is deleted upon ectopic 
expression of Cre recombinase (31). Upon Kras deletion, these MEFs lack all Ras isoforms, 
and become quiescent upon loss of all endogenous Ras activity. As was shown previously 
(31), we also determined that proliferation can be rescued by ectopic expression of activated 
BRAFV600E, or of wild-type versions of human KRAS4A, KRAS4B, HRAS, or NRAS. We 
established MEF cell lines using clonal populations from cultures infected with lentivirus 
expression vectors encoding each gene. Therefore, total RAS protein across the cell lines are 
comparable but most likely not equivalent (Fig. 2).
The results obtained with the three commercial pan-RAS antibodies in cell lines largely 
mirrored those using recombinant RAS proteins (Fig. 2A). Antibody 05–516 readily 
detected all RAS isoforms, albeit more weakly for KRAS4B. However, it also weakly 
detected a band in the Rasless MEFs expressing BRAFV600E that co-migrated with HRAS 
and NRAS, likely a RAS-related protein. As described above, three of the four FNLCR-
generated anti-KRAS4B antibodies display pan-RAS specificity, with CPTC-KRAS4B-2 
showing stronger and equivalent recognition of all RAS isoforms, no detection of any 
proteins in the ~21 kDa range in the Rasless MEFs expressing BRAFV600E, and faint 
recognition of other high MW cellular proteins (Fig. 2B). CPTC-KRAS4B-3 displayed 
similar pan-RAS reactivity and may better recognize NRAS. However, this antibody also 
weakly recognized a band in Rasless MEFs expressing BRAFV600E that migrates just above 
all the RAS isoforms; depending on the properties of the SDS-PAGE used to resolve cell 
lysates, this minor band may or may not be a concern in western blotting applications.
While both HRAS antibodies showed high specificity for the HRAS isoform, one (18295–1-
AP) recognized few other cellular proteins whereas the second (SC-520) also recognized 
numerous others (Fig. 2C). The NRAS antibody SC-31 showed high specificity for NRAS 
and no recognition of any ~21 kDa bands in Rasless MEFs expressing BRAFV600E (Fig. 
2D).
Of three putative KRAS4A/4B antibodies evaluated, both SC-30 and OP24 recognized both 
KRAS4A and KRAS4B and WH0003845M1 was highly selective for KRAS4B (Fig. 2E). 
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However, based on the much stronger recognition of recombinant KRAS4A protein by 
SC-30 and OP24 (Fig. 1D), we suspect that neither antibody would provide an accurate 
determination of how expression of the two KRAS isoforms at the RNA level is related to 
isoform expression at the protein level.
One KRAS4A-specific antibody (16156–1-AP) appeared to recognize KRAS4A but 
additionally recognized a closely co-migrating band in Rasless MEFs expressing 
BRAFV600E (Fig. 2F). In contrast, two other KRAS4A-specific antibodies selectively 
recognized KRAS4A but not KRAS4B, with no detection of any ~21 kDa bands in Rasless 
MEFs expressing BRAFVs600E (Fig. 2F). While both KRAS4B antibodies specifically 
detected purified recombinant proteins (Fig. 1D), neither detected KRAS4B in cell lysates, 
but strongly recognized numerous nonspecific proteins (Fig. 2G). Instead, our data indicate 
that WH0003845M1, although described as detecting both KRAS4A and KRAS4B, is the 
best available reagent for selective detection of KRAS4B. We conclude that there are many 
experimental conditions under which even antibodies commonly used in the literature may 
lead to erroneous interpretations.
RAS isoform detection in a human cell line
Our analyses in Rasless MEFs assessed detection of exogenously expressed human RAS and 
also revealed highly variable nonspecific recognition of mouse proteins. To assess detection 
of endogenous human RAS proteins and to evaluate nonspecific reactivity in human cells, 
we also evaluated several antibodies using lysates of HEK293T cells (Fig. 3A). Two pan-
RAS antibodies, 05–1072 and 05–516, recognized all RAS isoforms but also recognized 
other bands. The FNLCR antibody (CPTC-KRAS4B-2) that showed strong pan-RAS 
reactivity in Rasless MEFs expressing any RAS isoform without additional ~21 kDa bands 
in Rasless MEFs expressing BRAFV600E (Fig. 2B) also showed strong recognition of human 
RAS proteins and minimal recognition of nonspecific human proteins.
Neither HRAS-specific antibody detected any ~21 kDa band in HEK293T cells, indicating 
that these cells do not express significant endogenous HRAS. The NRAS-selective antibody 
SC-31 strongly recognized endogenous NRAS, with essentially no nonspecific reactivity.
Collectively, our results using the three commercially available KRAS4A/4B antibodies in 
all three model systems enable us to conclude that HEK293T cells express only KRAS4B, 
and that WH0003845M1 is superior to the two commercial KRAS4B-selective antibodies in 
recognizing endogenous human KRAS4B. Similarly, despite the strong detection by 16156–
1-AP of a ~21 kDa band in HEK293T cells, we conclude, based on our results using this 
antibody in Rasless MEFs, that this band(s) likely represents detection of RAS related 
proteins (e.g., RRAS isoforms). Finally, the lack of detection of any ~21 kDa band in 
HEK293T cells by the KRAS4A-specific antibodies SC-522 and ABC1442, coupled with 
the results from Rasless MEFs, validate both as excellent reagents for selective detection by 
western blotting of endogenous human KRAS4A but not KRAS4B protein. We suggest that 
such parallel analyses, using purified human RAS proteins, Rasless MEFs and human cells 
can more definitively identify the true specificity of RAS antibodies than any one system 
alone.
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Use of RNA interference for antibody validation in human tumor cell lines
Other experimental strategies to assist in validation of the RAS isoform selectivity of 
antibodies employs genetic knockdown using shRNA and siRNA to selectively target each 
RAS gene. Currently, no shRNA has been reported that can selectively silence each KRAS 
splice variant. Using a panel of human non-small cell lung carcinoma (NSCLC) cell lines, 
we first stably infected each line with lentivirus vectors encoding a non-specific sequence 
(NS) or two distinct targeted sequences (Table S1) for human HRAS, NRAS or KRAS (Fig. 
3B). Western blots on the resulting cell lysates with isoform-selective KRAS4A/4B and 
NRAS antibodies validated in Rasless MEFs expressing KRAS or NRAS (OP24 and SC-31, 
respectively). For comparison, we included an HRAS-selective antibody, SC-520, which 
failed in our validation experiments, to illustrate complications that may arise upon 
recognition of closely migrating nonspecific reactivity.
The protein levels detected by the KRAS4A/4B and NRAS antibodies were strongly reduced 
in cells stably expressing shRNA targeting KRAS and NRAS, respectively (Fig. 3B). In 
contrast, ~21 kDa bands were not reduced in cells stably expressing shRNA targeting HRAS 
and probed with the SC-520 antibody, suggesting that these HRAS-targeted shRNAs were 
not effective in silencing HRAS expression. However, the same analyses with a well-
validated second HRAS-selective antibody, 18295–1-AP, did show strong suppression of 
HRAS protein levels (Fig. 3C–3D). Thus, the apparent detection of HRAS protein by 
SC-520 likely reflects instead its strong detection of non-RAS proteins that migrate near 
HRAS (Fig. 2C). Table 2 provides a list of the isoform-specific, pan-RAS, and pan-KRAS 
(KRAS4A/4B) antibodies that we have validated for western blot applications, based on the 
above experiments.
With our validated antibodies, we could initially identify shRNAs that were selective for 
human KRAS or NRAS, without displaying off-target effects on other RAS isoforms. 
However, both of the original shRNAs targeting HRAS had isoform-specific off-target 
effects (Fig. 3C). To better identify an effective and selective HRAS shRNA, we further 
infected the panel of NSCLC lines with five additional HRAS shRNAs (Fig. 3D), and 
validated shRNAs that selectively suppressed HRAS. Our results using isoform-specific 
shRNAs are summarized in Supplementary Table S1.
Similarly, we evaluated isoform-specificity of siRNAs used to target different RAS isoforms 
in two RAS-mutant rhabdomyosarcoma cell lines. The protein levels detected by the specific 
antibodies were reduced in cells transiently transfected with the appropriate siRNAs (Fig. 
3E). In this instance, HRAS knockdown is clearly visible with the SC-520 antibody, 
suggesting the nonspecific band(s) that co-migrate with HRAS in NSCLC lines are not 
expressed in rhabdomyosarcoma lines (Fig. 3E–F), stressing our antibody validations are 
context and cell-type dependent. Notably, NRAS protein expression is reduced with KRAS 
siRNA1, HRAS siRNA2 decreases NRAS expression, and NRAS siRNA2 and siRNA3 
reduce HRAS expression. As done with the shRNAs, we further transfected these cells with 
additional KRAS, HRAS, and NRAS siRNAs and validated those that selectively suppress 
the correct isoform without targeting other RAS isoforms. Our results using isoform-specific 
siRNAs are summarized in Supplementary Table S2, and all siRNA and shRNA binding 
sites are shown in Fig. S1.
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Analysis of RAS G12D and G12V mutation-specific antibodies
We also tested two commercially available G12 mutant-specific RAS antibodies for their 
ability to recognize ectopically expressed mutant human KRAS4B in rescued Rasless MEFs 
expressing different mutant KRAS proteins and endogenous mutant KRAS in human 
KRAS-mutant cell lines (Fig. 4). These antibodies were very specific for the indicated 
mutant proteins. No background bands were detected in any of the lysates, even at extended 
exposure times. Notably, our data indicate that KRAS protein levels in Rasless MEFs 
expressing different mutant KRAS proteins are comparable to endogenous levels in the 
established cancer cell lines. However, while very specific for their targets, these mutation-
specific antibodies were considerably less sensitive than most of the isoform-specific 
antibodies. While we included only KRAS-mutant cell lines along with our controls in these 
experiments, these antibodies are also advertised to detect the G12D- and G12V-mutant 
forms of HRAS and NRAS.
RAS antibodies unsuitable for immunofluorescence of endogenous RAS proteins
We investigated whether any of the isoform- and mutant-specific RAS antibodies validated 
for use in western blotting could also be used for immunofluorescence (IF) detection of RAS 
proteins in Rasless MEFs (Fig. 5A). Our initial, baseline metric for suitability in IF was the 
lack of a significant signal in Rasless MEFs expressing BRAFV600E. Only one, the NRAS 
antibody SC-31, met this criterion (Fig. 5A). Notably, adherent Rasless MEFs expressing 
NRAS cover large surface areas when cultured on plastic or glass. Upon detaching these 
cells with trypsin, they are similar in size to Rasless MEFs expressing other RAS proteins in 
suspension. Moreover, the NRAS antibody selectively stained Rasless MEFs expressing 
NRAS, but not Rasless MEFs expressing KRAS4A, KRAS4B, or HRAS (Fig. 5B). The 
subcellular distribution of the signal was consistent with that of NRAS in our previous 
reports (32, 33). However, not all cells in each culture of Rasless MEFs expressing NRAS 
stained positively, presumably due to differing levels of NRAS expression.
Despite their utility in western blotting, both RAS mutation-specific antibodies also failed to 
be suitable for immunofluorescence (IF, Fig. 5C). The G12D-specific antibody picked up 
substantial background in Rasless MEFs expressing BRAFV600E. While the G12V-specific 
antibody did not appreciably stain Rasless MEFs expressing BRAFV600E, it did stain Rasless 
MEFs expressing any other RAS isoform. We suspect that the use of these antibodies in IF 
may be limited by their low sensitivity, as shown in our western blots, making it difficult to 
distinguish endogenous levels of RAS from background signals in individual cells.
Similarly, our attempts to detect endogenous wild-type (WT) and mutant NRAS in human 
cancer cell lines by IF, using the same SC-31 antibody that selectively stained Rasless MEFs 
expressing NRAS, were unsuccessful. We first validated by western blotting that we could 
deplete the endogenous NRAS signal in cancer cells harboring wild type NRAS [A375 cells] 
or mutant NRAS (Q61K) [SBC12 cells]. Despite near-complete NRAS knockdown (Fig. 
6A), the IF signal remained unchanged in each case (Fig. 6B).
It is widely appreciated that antibodies selected for utility in one application may not 
perform well in another (27). Importantly, western blots are performed under denaturing 
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conditions whereas IF detects proteins in more native conformations. Thus, while 
disappointing, it may not be entirely surprising that we have been unable to identify RAS 
antibodies suitable for both western blotting and immunofluorescence.
DISCUSSION
There is now a greater appreciation that there are RAS isoform-distinct biological roles in 
normal and neoplastic cells and that there are mutation-distinct functional consequences of 
these differences for RAS function (9). Research that aims to successfully address these 
differences requires the use of antibody reagents that have been rigorously validated for 
specificity and for utility in designated experimental applications. We recognize that the 
degree of validation of commercially available RAS antibodies is highly variable, and that 
rigorous validation is not feasible for the majority of research laboratories to perform on 
their own. The NCI Ras Initiative was established in part to address such gaps in the field 
(29). We completed studies that critically assessed 22 commercially available RAS 
antibodies, including those most widely used in the literature. Our goals were to identify 
potential limitations of each antibody, to rigorously validate antibodies for use in the field in 
specific applications, and ultimately to establish how accurately it is possible to interpret 
data acquired using each antibody. A critical component of our analyses was the utilization 
of a unique panel of Rasless MEFs expressing BRAFV600E or other RAS isoforms. With this 
well-validated panel, which we established at the NCI RAS Initiative, coupled with our 
analyses of recombinant unprocessed and processed human KRAS4A/4B proteins and by 
using shRNA vectors targeting each RAS gene, we were able to very rigorously assess RAS 
specificity and isoform selectivity under different experimental conditions. We have 
identified antibodies that selectively recognize each of the four human RAS proteins in 
human cancer cells, thereby identifying a set of RAS antibodies that can be used with 
confidence in future studies employing western blot analyses. Our survey did not identify 
RAS antibodies useful for other experimental applications such as immunofluorescence or 
immunohistochemistry.
Consistent with perceptions of the antibody field in general (20–22), we found a broad 
spectrum of RAS antibody quality, from poor to excellent. Overall, the majority of these 
antibodies displayed their vendor-described specificities, but several vendors provided 
incomplete or overstated information that may lead to misinterpretation of data.
Given the high overall amino acid sequence identity of RAS proteins (9), many antibodies 
generated against one specific RAS isoform will also recognize other RAS isoforms. For 
example, while monoclonal antibody CPTC-KRAS4B-2 was generated against KRAS4B, 
the name is misleading in that it suggests KRAS4B selectivity. Instead, we found that 
CPTC-KRAS4B-2 was the most effective pan-RAS antibody available, and can provide a 
useful reagent to determine overall total RAS protein expression in cells. However, this 
antibody may also recognize other ~21 kDa small GTPases with sequence similarity to RAS. 
Since ectopic expression of other small GTPases cannot restore the growth of Rasless MEFs 
(31), we do not have reagents to address potential antibody selectivity for such proteins with 
similar rigor as done here for RAS. Conversely, one polyclonal antibody generated against 
recombinant NRAS poorly recognized recombinant NRAS, showed stronger recognition of 
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other recombinant RAS proteins, and failed to detect NRAS in our panel of rescued Rasless 
MEFs expressing other RAS isoforms. Thus, while it did identify a ~21 kDa band in 
HEK293T cells, we suspect that the detected band is not NRAS. Finally, while the product 
information provided with this antibody showed that it recognizes only a single ~21 kDa 
band in HEK293 cell lysates, with no recognition of other cellular proteins, our analyses in 
both Rasless MEFs and HEK293T cells found very significant nonspecific reactivity. These 
and other examples emphasize the critical value of Rasless MEFs in evaluating RAS 
antibody selectivity and utility in different experimental applications.
Of the two KRAS splice variants, KRAS4B has been by far the most studied in the cancer 
field, due in large part to availability of reagents and a widely held perception that the 
KRAS4B splice variant is the predominant KRAS protein expressed in human tumor cells 
(5). However, in the absence of antibodies capable of distinguishing KRAS4A and 
KRAS4B, this perception was based on early studies of KRAS expression at the level of 
mRNA, not protein. Ironically, the very first discovery of KRAS as an oncogene was of the 
Kirsten murine sarcoma virus, which encodes a G12-mutated rat KRas4A protein (34). 
Furthermore, our studies found that 30 of 30 human cancer cell lines express both KRAS4A 
and KRAS4B mRNA, and that, in colorectal carcinoma tissues, KRAS4A and KRAS4B 
transcripts are similarly abundant (6). Our analyses here did identify useful antibodies for 
selective detection of KRAS4A and KRAS4B proteins. Regarding KRAS4B-selective 
antibodies, we found that the two commercially available antibodies, while clearly selective 
when evaluated using recombinant proteins, did not effectively recognize cell-expressed 
KRAS4B protein in Rasless MEFs. One antibody did detect ~21 kDa bands, but the 
equivalent detection of such bands in the Rasless MEFs expressing BRAFV600E demonstrate 
that this antibody does not detect cellular KRAS4B expression. Instead, we found that the 
best KRAS4B-selective antibody was one described as detecting both KRAS4A and 
KRAS4B. We did validate two useful KRAS4A-selective antibodies, with each having 
distinct nonspecific activities that do not compromise their application in western blots, but 
likely limit their usefulness in other applications. Currently, whether KRAS4A and 
KRAS4B serve distinct driver roles in cancer is not known. To date, the relative expression 
of the two KRAS splice variants has been determined only at the RNA level. Validated 
KRAS splice variant-selective antibodies will provide crucial reagents to accurately address 
this issue. Furthermore, using our validated antibodies, we identified shRNA constructs 
selective for each RAS isoform that can assist in determining the specificity of additional 
antibodies.
Finally, we validated two mutation-specific antibodies for western blot detection of RAS 
proteins with G12D or G12V mutations (which comprise 59% of all KRAS mutations), 
supporting the feasibility of developing additional antibodies selective for other common 
RAS mutations. Current assays to detect GTP-bound RAS are not amenable to 
immunohistochemical (IHC) evaluation of patient tumor tissue. Unfortunately, these 
mutation-selective antibodies were also not useful for IHC analyses of formalin-fixed, 
paraffin-embedded or frozen tissue from two cases harboring previously identified 
KRASG12D and KRASG12V mutations, even though western blot analyses of tissue from the 
same two cases confirmed expression of the G12D or G12V mutant RAS proteins (Fig. S2). 
Thus, these antibodies cannot selectively measure activated RAS in patient tissue.
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In summary, we have performed comprehensive analyses of the selectivity of a large panel 
of RAS antibodies, and achieved our goal of validating antibodies that are useful for western 
blot detection of each of the four RAS proteins as well as of the two KRAS mutations most 
prevalent in cancer. Our studies also emphasize the need for well-validated RAS antibodies 
for other experimental applications, in particular for immunofluorescence analyses of 
endogenous RAS proteins, where our current knowledge of the spatial distribution of RAS 
proteins has relied exclusively on the study of exogenously expressed proteins. With the 
possible exception of a validated NRAS-selective antibody, we did not identify RAS 
antibodies useful for immunofluorescence analyses. Although many commercially available 
RAS antibodies are described as being useful for immunofluorescence (Table 1), our 
findings stress that more rigorous validation of antibody utility in specific applications, 
beyond simply detecting signal, needs to be done. We did not evaluate the usefulness of 
RAS antibodies for immunoprecipitation (IP) or (with the exception of G12 mutation-
specific antibodies), for immunohistochemistry, although the inability of the antibodies we 
tested to perform well in IF suggests they may also not work well in IP applications. We did 
not evaluate all commercially available RAS antibodies. Nevertheless, our western blot 
results can serve as a resource and guide for further qualifying RAS antibodies for additional 
applications.
MATERIALS AND METHODS
E. coli expression and purification of human RAS proteins
Recombinant proteins were expressed as His6-MBP-tev-RAS fusion proteins in E. coli 
(BL21Star™ (DE3) pRare) and purified as we described (35). After proteolytic cleavage of 
the N-terminal tags, the final proteins generated were GlyGlySerGly-KRAS4B (2–188), 
Gly-HRAS (1–189), and Gly-NRAS (2–189). Protein concentrations were determined by 
UV280 using an extinction coefficient of 19865 M-1 cm-1 (11,920 from protein, 7945 from 
GDP) (36).
Insect cell expression and purification of KRAS4A and KRAS4B
Expression and purification of processed GlyGly-Hs.KRAS4A (2–189) and GlyGly-
Hs.KRAS4B (2–188) were performed as we described previously, using a bacmid 
engineered to co-express FNTA and FNTB (35). Expression of non-processed GlyGly-
Hs.KRAS4A and GlyGly-Hs.KRAS4B followed the same protocol except that the 
expression constructs were cloned into the standard bacmid. Purification of processed 
KRAS4B was performed as we described (35), whereas processed KRAS4A was purified 
using a modified protocol that added an anion exchange step after the initial capture from 
lysate. Non-processed KRAS4B was purified as we described previously (30).
Establishment of Rasless MEFs with isoform-specific RAS protein production
A clonal panel of MEF cell lines containing single transgene alleles was generated using the 
Rasless MEF system developed by Barbacid and colleagues (31). MEFs null for both Hras 
and Nras (provided by M. Barbacid) were treated with 600 nM 4-hydroxytamoxifen (4-
OHT) for 9 to 11 d to remove the endogenous floxed KRAS gene. Cells lacking all 
endogenous Ras proteins arrest in G1, but resume proliferation upon lentiviral delivery of an 
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ERK MAPK pathway activating gene (e.g., RAS or BRAF). Alternatively, cell line pools 
were generated through lentiviral transduction and antibiotic selection followed by treatment 
with 4-OHT and single-cell cloning. A single-cell clone was validated for each transgene. 
Confirmation of endogenous Kras gene removal was performed by western blotting and 
sequencing.
RAS antibody generation
Purified unprocessed full length wild type KRAS4B (30) was submitted for antibody 
generation at Precision Antibody Inc. Candidate clones were screened at the Antibody 
Characterization Lab (ACL; FNLCR) following procedures outlined on the antibody portal 
website (http://antibodies.cancer.gov). Four candidates were selected based on reactivity by 
western blot on a WES instrument (Protein Simple) and using the immunoprecipitation mass 
spectrometry method developed by the ACL. All antibodies and characterization data can be 
found on the ACL web portal, and antibodies and hybridomas are available through the 
Developmental Studies Hybridoma Bank (University of Iowa).
SDS-PAGE
Each purified RAS protein was diluted to 1X in NuPage LDS loading buffer (Invitrogen), 
containing 25 mM TCEP (Sigma-Aldrich) to final protein concentrations of 3, 1, and 0.3 µg 
per 10 µL and applied to 10–20% gradient Criterion 26-well Tris-HCl precast gels (Bio-Rad) 
in 1X Tris-Glycine-SDS running buffer. Benchmark™ protein ladder size standards (Thermo 
Fisher Scientific) flank each set of proteins. Gels were stained with SimplyBlue SafeStain 
(Thermo Fisher), then imaged in a Fujifilm LAS-3000 equipped with an LAS-4000 CCD 
camera.
Western blots
For purified protein, each RAS protein was diluted to 1X in NuPage LDS loading buffer 
containing 25 mM TCEP to final protein concentrations of 10, 1, and 0.1 ng per 10 µL and 
denatured by heating to 70°C for 10 min. Western blots were performed as described 
previously (37). Cells were lysed in 1% Triton detergent buffer and assayed for protein 
content using the BCA assay (Pierce Biotechnologies). Twenty µg of each lysate in NuPAGE 
LDS sample buffer were loaded into wells of 12% Criterion TGX Stain-Free Gels (Bio-Rad) 
to the right of a MagicMark™ XP protein ladder (Thermo Fisher Scientific). The resolved 
proteins were transferred to methanol-activated PVDF membranes for 90 min in 1X Transfer 
Buffer (25 mM Tris, 94 mM glycine, 20% methanol) at currents maintained between 350–
450 mA. After blocking in 3% non-fat dry milk and washing in TBS-Tween, membranes 
were incubated overnight in 10 µg of primary antibody diluted in 10 ml of 3% dry milk in 
1X TBS-T. Membranes were washed again and rocked at room temperature for 1 h in HRP-
labeled secondary antibody (horse anti-mouse, Cell Signaling #7076 or goat anti-rabbit, Cell 
Signaling #7074) diluted 1:2000 in 3% dry milk in TBS-Tween. After washing, membranes 
were developed with Amersham ECL Prime Western Blotting Detection Reagent (GE 
Healthcare) in a ChemiDoc Imaging System (Bio-Rad). Anti-vinculin (V9131) or anti-
GAPDH (G8795) antibodies (1:5000, Sigma-Aldrich) were used as loading controls. Blots 
were not stripped prior to probing for loading controls. A full list of RAS antibodies can be 
found in Table 1.
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Cell culture
Rescued Rasless MEFs, generated at FNLCR as described above, were maintained in 
DMEM (Corning, Inc.) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich). 
Established human cancer cell lines were obtained from the American Type Culture 
Collection (ATCC) and maintained in RPMI-1640 (Corning, Inc.; NSCLC cancer lines) or in 
DMEM (Corning; melanoma cell lines) supplemented with 10% FBS. Cell line identities 
were confirmed by STR analysis.
shRNA knockdowns of specific RAS isoforms
Lentivirus virus-like particles expressing shRNAs targeted against different RAS transcripts 
were produced in HEK293T cells by transfection of a 4:3:1 ratio of NRAS (or nonspecific) 
shRNA plasmid:psPAX2:pMD2.G and a 1:3 ratio of DNA:Fugene 6 (Promega). Sequences 
targeted by each shRNA are provided in Table S1.
Immunofluorescent laser scanning confocal microscopy
All rescued Rasless MEFs expressing BRAFV600E or RAS isoforms were plated at a density 
of 4 × 104 cells in 12-well No 1.5 Mattek plates with 14 mm coverslips (Mattek 
Corporation) and grown for 24 to 48 h before fixing in 2% paraformaldehyde for 15 min at 
room temperature, 4% paraformaldehyde for 5 minutes at room temperature, or 100% 
methanol for 20 min at −20°C. Paraformaldehyde-fixed cells were permeabilized with 0.1% 
Triton X-100 in 1X PBS for 15 min. All cells were then incubated in blocking buffer 
(Rockland) containing 0.1% Triton X-100 for 45 min at room temperature. Cells were 
incubated overnight in 1:100 dilutions of each RAS antibody. Cells were then incubated in 
1:300 goat anti-mouse or goat anti-rabbit AlexaFluor488 (Invitrogen) in blocking buffer 
+ 0.1% Triton X-100. Ten min prior to completion of secondary antibody incubation, a 
1:100 dilution of 50 µg/ml DAPI (Thermo Fisher) was added to each well to stain nuclei. 
After washing, cells were imaged in a Zeiss LSM700 scanning confocal microscope with a 
40X oil immersion lens. Images were analyzed using ZEN Blue software (Carl Zeiss). 
Changes in fixation method did not affect localization, except with anti-HRAS. Methanol 
fixation of Rasless MEFs expressing HRAS led to loss of nuclear staining in both Rasless 
MEFs expressing BRAFV600E or NRAS. Otherwise, the nonspecific signal was preserved. 
All images shown are from cells fixed in 2% paraformaldehyde, except for WH0003845M1 
KRAS images, which were from methanol-fixed cells.
For co-localization experiments in melanoma lines, A375 and SBC12 cells were fixed in 2% 
paraformaldehyde for 15 min at room temperature. To visualize the plasma membrane, 
wheat germ agglutinin AlexaFluor647 conjugate (Thermo Fisher, W33466) labeling solution 
(5 µg/ml in 250 µl) was added to each well and incubated for 10 min at 37°C. For 
endoplasmic reticulum (ER) or Golgi labeling, anti-PDI (Invitrogen, MA3–019) or anti-
GM130 (610823) (BD Biosciences) was incubated on the cells overnight (1:300), followed 
by goat anti-mouse Alexafluor568 for 45 min at room temperature. Cells were washed and 
imaged in a Zeiss LSM700 with a 63X oil immersion lens. Images were analyzed using 
ZEN Blue software.
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Immunohistochemistry on formalin-fixed and frozen sections of human tumor tissues
Immunohistochemistry was performed on 4-μm-thick formalin-fixed, paraffin-embedded de-
identified patient tumor sections using the Discovery XT automated system (Ventana 
Medical Systems). Sections were mounted on charged glass slides and baked at 60°C for 1 h 
before heat-induced antigen retrieval was performed using standard CC1 (Cell Conditioning 
1 solution). Slides were incubated with G12D- (14429) or G12V- (14412) selective 
antibodies for either 2 h at room temperature (UltraMap protocol) or 1 h with heat 
(DABMap protocol). Chromogenic detection was done with the DABMap kit or the 
UltraMap DAB anti-Rb kit. Four-μm-thick frozen sections were fixed in neutral buffered 
formalin for 10 min before the assay was performed on the Discovery Ultra automated 
system (Ventana). Slides underwent 36 min of CC1 treatment before incubation with G12D 
or G12V antibodies, titrated at 1:100, for 60 min at 37°C. Detection was completed with the 
DABMap kit.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Selectivity of RAS antibody detection of purified RAS proteins
Three different concentrations of E. coli (Ec)- or insect cell-expressed unprocessed (UP) or 
processed (P) purified RAS proteins were resolved by SDS-PAGE and (A) stained with 
Coomassie blue to show protein loading, or subjected to western blot analysis using a panel 
of RAS antibodies: (B) pan-RAS, (C) HRAS- or NRAS-selective, and (D) “pan-KRAS” 
KRAS4A/4B-, or KRAS4A- or KRAS4B-selective.
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Fig. 2. RAS antibodies detect both RAS and also background bands and nonspecific 21-kDa 
bands in lysates of rescued Rasless MEFs
Western blot analyses were performed with (A,B) pan-RAS, (C) HRAS-, (D) NRAS-, (E) 
KRAS4A/B-, (F) KRAS4A- or (G) KRAS4B-selective antibodies on total cell lysates from 
Rasless MEFs ectopically expressing the indicated proteins. Vinculin (A-F) or background 
nonspecific bands (G) served as a loading control. Full (uncut) blots, including MagicMark 
XP size standards in the left lane of each panel, are shown to reveal degree of nonspecific 
protein recognition.
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Fig. 3. RAS antibodies detect both endogenous RAS and nonspecific background bands in 
human cell lysates
(A) HEK293T cell lysates were probed by western blotting with the indicated RAS 
antibodies. Full (uncut) blots, including molecular weight markers in the right lane of each 
panel, are shown to reveal the degree of nonspecific protein recognition. (B, C) To determine 
isoform selectivity of shRNAs, human NSCLC cell lines were infected with lentivirus 
vectors encoding shRNAs targeting the indicated RAS genes. Cell lysates were probed by 
western blotting with the indicated RAS antibodies. Vinculin served as a loading control. 
(D) To identify HRAS-selective shRNAs, 7 HRAS-targeting constructs were infected into 
NSCLC cells and probed with the indicated RAS antibodies. (E, F) To determine isoform 
selectivity of siRNAs, rhabdomyosarcoma cell lines were transfected with siRNAs targeting 
the indicated RAS genes. Cell lysates were probed by western blotting with the indicated 
RAS antibodies. β-actin served as a loading control.
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Fig. 4. Mutation-specific RAS antibodies detect mutant KRAS proteins in MEFs and human 
cancer cell lines with high fidelity
Western blotting was performed with G12D- (upper panel) and G12V- (lower panel) 
mutation-specific antibodies to probe (left) Rasless MEFs rescued with the indicated 
mutants of human KRAS (or WT RAS or BRAF controls), or (right) KRAS-mutant cancer 
cell lines. All cell lines except HCT116 are homozygous for mutant KRAS. Full (uncut) 
blots are shown to reveal the absence of nonspecific protein recognition. Blots were probed 
with KRAS4B antibody to show total KRAS protein. GAPDH served as a loading control.
Waters et al. Page 20
Sci Signal. Author manuscript; available in PMC 2018 March 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 5. An immunofluorescence (IF) signal from isoform- or mutation-specific RAS antibodies 
does not reliably indicate the presence of the relevant RAS protein
(A) The indicated RAS isoform-selective antibodies were used in IF analyses of Rasless 
MEFs expressing solely the relevant RAS isoform or BRAFV600E. (B) To determine the 
RAS isoform selectivity of the NRAS SC-31 signal shown in panel A, the same antibody 
was used to probe Rasless MEFs expressing each RAS isoform. (C, D) RASG12D- or 
RASG12V-mutation specific RAS antibodies were used for IF analyses of Rasless MEFs 
expressing the relevant KRAS mutant or BRAFV600E negative control (C, KRASG12D) or 
WT RAS isoforms (D, KRASG12V). Scale bars, 20 µm; blue, DAPI nuclear stain; green, 
goat anti-rabbit or anti-mouse AlexaFluor488, to detect each primary RAS antibody.
Waters et al. Page 21
Sci Signal. Author manuscript; available in PMC 2018 March 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 6. NRAS antibody can detect endogenous NRAS protein by western blot but not by 
immunofluorescence
(A) Immunoblot showing shRNA knockdown of NRAS protein in A375WT and SBcl2Q61K 
melanoma cell lines. (B) Representative images of IF analyses performed as in Fig. 5, but in 
A375 and SBcl2 cells knocked-down with nonspecific (NS) or NRAS shRNA and co-stained 
with NRAS (SC-31) antibody and co-localization markers for plasma membrane (wheat 
germ agglutinin), endoplasmic reticulum (PDI), or Golgi (GM130). Scale bars, 10 µm; blue, 
DAPI nuclear stain; green, RAS; red, organelles.
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Table 2
Validated RAS antibodies
Isoform Validated Antibodies Comments
HRAS/KRAS/NRAS
CPTC-KRAS4B-2 Nonspecific bands above 50 kDa, very sensitive
05–1072 Nonspecific bands above 30 kDa
HRAS 18295–1-AP Nonspecific bands above 30 kDa
NRAS SC-31 May be useful for IF in overexpression models
KRAS4A/4B OP24*/SC-30* No IF
KRAS4B WH0003845M1 Very sensitive, no IF
KRAS4A
ABC1442 Nonspecific bands above 40 kDa, may have difficulty detecting endogenous levels, no IF
SC-522 Nonspecific bands above 30 kDa, may have difficulty detecting endogenous levels, no IF
*
same clone
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